NASDAQ:IART

Integra Lifesciences Holdings Stock News

etoro logo Buy IART
*Your capital is at risk
$16.10
+0.430 (+2.74%)
At Close: Jun 03, 2026
Integra Lifesciences (NASDAQ:IART) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com r
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New York, April 30, 2020 -- Reportlinker.com announces the release of the report "Global Soft Tissue Repair Market - Premium Insight, Competitive News Feed Analysis, Company.
The "China Catheters Market 2019-2025" report has been added to ResearchAndMarkets.com's offering.
After Wells Fargo and Goldman Sachs gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received another Buy, this time from
After Wells Fargo and Goldman Sachs gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received
Macquarie Group Ltd. grew its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 13.6% during the fourth quarter, according to the company in its most recent 13F filing with the
Nisa Investment Advisors LLC boosted its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 8.9% during the first quarter, according to the company in its most recent filing with the Secu
Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) during the 1st quarter, according to the company in its most recent 13F fili
Credit Suisse analyst Matt Miksic maintained a Buy rating on Edwards Lifesciences (EW) today and set a price target of $262.00. The company's shares
Credit Suisse analyst Matt Miksic maintained a Buy rating on Edwards Lifesciences ( EW – Research Report ) today and set a price target of $262.00 . The company’s shares closed last Friday at $223
In a report released today, Steven Lichtman from Oppenheimer assigned a Buy rating to Merit Medical Systems (MMSI), with a price target of $46.00. The
In a report released today, Steven Lichtman from Oppenheimer assigned a Buy rating to Merit Medical Systems ( MMSI – Research Report ), with a price target of $46.00 . The company’s shares closed
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE